Lumicell

04/22/2026

Now live 🎥

We’re proud to share Lumicell’s feature on Health Uncensored with Dr. Drew!

The segment focuses on the challenges surgeons face in identifying residual cancer during lumpectomy procedures and the potential impact of enhanced intraoperative visualization.

Watch here: https://www.youtube.com/watch?v=86LUsJhMhJE

Important Safety Information:
The most common side effects with LUMISIGHT(TM) (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/) . For complete product information, visit www.LumiSystem.com.

1 like. "Changing the Face of Surgical Oncology"

04/14/2026

We’re excited to share that Lumicell will be featured on Health Uncensored with Dr. Drew, discussing advances in breast cancer surgery and the role of enhanced intraoperative visualization.

The segment, “Transforming Cancer Surgery,” features Dr. Fedra Fallahian, breast surgical oncologist, Jorge Ferrer PhD, Lumicell’s Chief Scientific Officer, and Kristie Cole, breast cancer patient, in an in-studio conversation focused on surgical decision making and the patient experience.

📺 Tune in April 19th at 5:00PM ET on Fox Business!

04/10/2026

We are heading to Seattle for ASBrS2026 and look forward to connecting with attendees!
📅 April 29-May 3

Lumicell is planning lots of opportunities to engage – join us!

Visit our Booth 423 for a hands-on demo and interactive experience featuring LumiSystem® the only intraoperative technology that illuminates suspected residual cancer in the breast cavity.

Meet our Leadership team, including our VP of Innovation, VP of Sales, and VP of Research & Development for meaningful scientific discussions. Plus, join them for relaxed clinical conversation over dinner Friday May 1 or Saturday May 2.

Attend our curated elegant dinner presentation Intraoperative Insights: A Clinical Dinner Discussion, Thursday April 30, featuring Dr. Fallahian.

Bonus for Breast Fellows! We are sponsoring The Fellows Workshop Thursday April 30, 7am-3:30pm and will be onsite with hands-on demos. Catch us there!

Let’s meet in Seattle!

03/31/2026

Surgeons use imaging and localization tools to guide lumpectomy, but cannot see what may remain in the breast cavity or confirm clear margins in real-time. Confirmation comes days later with pathology results.

LumiSystem™ is the first and only intraoperative technology that helps visualize suspected residual cancer to inform surgical decisions when it matters most.

Learn more at
https://lumisystem.com/

03/24/2026

We are excited to invite ASBrS 2026 attendees to our exclusive educational dinner program.

Join us for thoughtful engagement with colleagues on the importance of intraoperative insight during breast-conserving surgery.

This is an opportunity to discuss:
• Surgical standard of care limitations
• The clinical evidence and practical application of LumiSystem® to support surgical decisions and outcomes

Intraoperative Insights: A Clinical Dinner Discussion
Featuring: Dr. Fedra Fallahian, Breast Surgical Oncologist 👩‍⚕️
📅 Thursday, April 30th
🕡 6:30 PM
📍 The Capital Grille
1301 4th Ave, Seattle, WA 98101
⚠️ Seating is limited
📩 RSVP: Shannon Butler at sbutler@lumicell.com

Important Safety Information:
The most common side effects with LUMISIGHT™ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/) including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/) For complete product information, visit www.LumiSystem.com.

03/17/2026

Despite advances in imaging and pathology, unseen residual disease in the breast cavity remains a persistent risk during a lumpectomy.

LumiSystem is the first and only intraoperative technology that enables surgeons to scan inside the breast cavity for residual cancer that may have otherwise been left behind.

Learn more
https://lumisystem.com/

03/11/2026

Residual disease after lumpectomy creates downstream challenges that extend far beyond the OR.

See how LumiSystem helps illuminate suspected cancer in the breast cavity during lumpectomy to support improved surgical outcomes.

Learn More
https://lumisystem.com/learn-about-lumisystem

03/07/2026

Up to one-third of lumpectomies fail to achieve a complete resection due to limited interoperative visibility*. Real-time cavity scanning addresses that.

LumiSystem is the only intraoperative adjunct technology that illuminates suspected cancer in the breast cavity when decisions matter most.

Learn more https://lumisystem.com/


*Dupont et al., 2021

03/02/2026

If you could see what’s left behind…wouldn’t you want to?

Come see the only interoperative adjunct technology that illuminates residual cancer in real time during lumpectomy. Surgeons get a clearer view inside the cavity to support more confident decisions.

Visit Lumicell at Booth T11 at the 43rd Annual Miami Breast Cancer Conference, March 5-8.

Important Safety Information:
The most common side effects with LUMISIGHTTM (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

02/23/2026

🗓️ Feb 28, 2026 | 📍 NYC
Lumicell is exhibiting at the New York Metropolitan Breast Cancer Group 52nd Annual Breast Cancer Symposium!

We’re excited to see the important topic of intraoperative margin assessment on the agenda for the meeting. If you're attending, make sure to tune in and stop by our table to learn more!

02/17/2026

We are excited to connect with surgeons, oncologists and the broader breast cancer care community at the 43rd Annual Miami Breast Cancer Conference®, March 5-8.

Visit the Lumicell booth to see how our real-time visualization technology can advance confidence in breast-conserving surgery. As the only adjunct technology that illuminates residual cancer within the breast cavity, it provides actionable insight to support more complete resections and better surgical outcomes.

We’d love to show you what is possible to advance surgical precision.

See you in Miami!

02/10/2026

Pathology margin assessment in breast-conserving surgery continues to face critical limitations—including false readings, tissue distortion, and the inability to fully evaluate the specimen surface. These gaps leave room for residual disease to go undetected.

Advances in intraoperative imaging enable real-time scanning inside the breast cavity, providing surgeons with immediate insight into residual cancer that traditional methods may miss.

Lumicell’s intraoperative adjunct visualization technology is designed to illuminate residual breast cancer when surgical decisions matter most.